SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (367)8/12/1999 3:06:00 PM
From: scaram(o)uche  Respond to of 3044
 
Thursday August 12, 2:45 pm Eastern Time

Company Press Release

SOURCE: Millennium Pharmaceuticals, Inc.

Millennium Delivers Two Cancer Drug Candidate
Genes to Eli Lilly

- Delivery of Candidate Genes in Prostate Cancer and Drug Resistance
Trigger Milestone Payments -

CAMBRIDGE, Mass., Aug. 12 /PRNewswire/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - news) today
announced that one of its partners in oncology, Eli Lilly and Company (NYSE: LLY - news), has accepted two candidate
genes for use in the development of new small-molecule cancer therapeutics. These achievements trigger two undisclosed
milestone payments from Lilly to Millennium. (snip)